MCL Literature Feed

An AI-based platform provides more objective and reproducible immunohistochemistry quantification than manual interpretation, improving the diagnostic accuracy in differentiating MCL from CLL/SLL.

This UK real-world study shows chemotherapy bridging before brexu-cel yields higher responses than targeted therapy but causes more toxicity and early mortality without improving post-CAR-T survival.

Frontline zanubrutinib-rituximab induction achieved an 88% complete response rate, enabling a shortened R-DHAOx consolidation, offering a highly effective, chemotherapy-de-escalation strategy for newly diagnosed MCL.

High serum sTNFR2 at diagnosis is a strong prognostic biomarker for inferior overall survival in MCL, implicating the tumor microenvironment and suggesting a new therapeutic target.

This study identifies the SOX11-UHRF1 axis as a new therapeutic target in MCL, demonstrating that the UHRF1 inhibitor CM272 effectively suppresses tumor growth in preclinical models.

Brexucabtagene autoleucel demonstrates high efficacy (91% ORR, 73% CR) in BTKi-naive relapsed/refractory MCL, supporting its use as an effective option before BTKi failure in high-risk patients.

A novel single-cell technique, LiP-Seq, identified IFITM2 upregulation in rare persistent MCL cells post-CAR-T, revealing a new mechanism of immune evasion and a potential therapeutic target.

An expert panel opinion advocates for personalized MCL therapy, positioning BTKi as a frontline standard for transplant-ineligible patients and a potential alternative to consolidation transplant for others.

The novel BCL-2 inhibitor lisaftoclax demonstrated a 50% overall response rate and manageable safety in a phase 1 trial of Chinese patients with relapsed/refractory MCL.

Absence of CD38 expression in conventional nodal MCL strongly correlates with TP53 inactivation and a distinct genetic profile, identifying a high-risk subgroup via routine flow cytometry.

This German real-world study (2015-2020) reveals rising MCL incidence and poor outcomes, highlighting a dismal median OS of 3.0 months after cBTKi discontinuation, underscoring a critical unmet need.

Dual inhibition of anti-apoptotic proteins BIRC5 and MCL-1 is a novel preclinical strategy to overcome drug resistance in mantle cell lymphoma, offering a potential new therapeutic avenue.

In a real-world R/R MCL cohort, zanubrutinib demonstrated significantly longer overall survival versus ibrutinib and favorable trends versus acalabrutinib, guiding clinical selection of covalent BTKis.

The NAMPT inhibitor KPT-9274 sensitizes TP53-mutated MCL to alkylating chemotherapy by disrupting the DNA damage response, offering a novel combination strategy for this high-risk, chemo-resistant population.

A family history of hematological malignancy is associated with inferior event-free survival in mantle cell lymphoma, suggesting it may be a novel adverse prognostic factor.

Adding ibrutinib to intensive frontline immunochemotherapy for newly diagnosed, fit MCL patients aims to deepen responses and improve outcomes, often as induction before transplant consolidation.

Preclinical data shows that inhibiting the cell cycle regulator CDC20 suppresses MCL growth by downregulating the PI3K/AKT pathway, identifying CDC20 as a novel therapeutic target.

Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.

This Chinese real-world study characterizes the clinical features and poor prognosis of blastoid/pleomorphic MCL, providing data to help risk-stratify and manage this aggressive subtype.

This meta-analysis suggests zanubrutinib monotherapy yields superior complete and overall response rates over ibrutinib and acalabrutinib in relapsed/refractory MCL, informing optimal BTKi selection.

A novel preclinical compound dually inhibiting FLT3 and HDAC is developed, introducing a new potential therapeutic mechanism for hematologic malignancies, though its specific relevance to MCL is unknown.

This first comprehensive proteogenomic analysis of MCL demonstrates that integrating protein data with genomics improves survival prediction and identifies molecular subtypes linked to IGHV/CCND1 mutations, offering new prognostic tools.

A case of CD5+ cutaneous DLBCL highlights a diagnostic pitfall, as it can mimic MCL but is distinguished by cyclin D1 negativity, reinforcing the need for complete immunohistochemical workup.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

A novel liquid biopsy technique using cell-free chromatin profiling non-invasively tracks disease origin and monitors therapy response, offering a powerful new tool for MRD and biomarker discovery.

Proteomic profiling identified an MCL-specific protein signature, including seven targets missed by RNA analysis, offering novel avenues for CAR-T therapy and personalized treatment.

The oral AKT inhibitor capivasertib showed modest single-agent activity (30% ORR) in relapsed/refractory MCL, with PTEN deficiency emerging as a potential predictive biomarker for patient selection.

This large epidemiological study identifies mantle cell lymphoma as one of the most frequent and aggressive nodal non-Hodgkin lymphoma subtypes in North Africa, highlighting regional disease patterns.

A case report demonstrates repeated MCL progression upon initiation of the JAK-1 inhibitor upadacitinib for psoriatic arthritis, suggesting a potential role for JAK signaling in promoting MCL growth.

Bridging radiotherapy before CAR-T effectively controls disease in MCL patients, with most showing rapid tumor reduction and no local progression, supporting its use as a pre-CAR-T strategy.